Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Dec 30.
Published in final edited form as: J Immunol. 2009 Dec 9;184(2):859–868. doi: 10.4049/jimmunol.0903149

An NZW-derived interval on chromosome 7 moderates sialadenitis, but not insulitis in congenic NOD mice1

Rachel A Burt , Laura Watkins †,, Iris Kwee Ling Tan *,, Nancy Wang *,, Fiona Quirk , Leanne Mackin *, Phillip Morgan , Jian-Guo Zhang , Stuart P Berzins §, Grant Morahan , Thomas C Brodnicki *,2
PMCID: PMC9800181  NIHMSID: NIHMS179694  PMID: 20007538

Abstract

Autoimmune lymphocytic infiltration of the salivary glands, termed sialadenitis, is a pathological feature of Sjögren’s syndrome (SjS) that is also prominent in nonobese diabetic (NOD) mice. Genetic factors regulate sialadenitis and a previous (NOD × NZW)F2 study detected linkage to murine chromosome (Chr) 7. The locus, subsequently annotated as Ssial3, maps to the distal end of Chr7 and overlaps a region associated with type 1 diabetes susceptibility in NOD mice. To examine whether Ssial3 could contribute to both diseases, or was specific for SjS, we generated a congenic mouse strain that harboured an NZW-derived Chr7 interval on the NOD genetic background. This congenic strain exhibited reduced sialadenitis compared to NOD mice and confirmed Ssial3. This reduction, however, did not ameliorate saliva abnormalities associated with SjS-like disease in NOD mice, nor were congenic mice protected against insulitis (lymphocytic infiltration of the pancreatic islets) or diabetes onset. Thus, the Ssial3 locus appears to have a tissue specific effect for which the NZW allele is unable to prevent other autoimmune traits in the NOD mouse. Anomalous increases for anti-nuclear antibody production and frequency of marginal-zone B-cells were also identified in congenic mice indicating that the NZW-derived Chr7 interval has a complex effect on the NOD immune system.

Keywords: Sjögren’s syndrome, Type 1 diabetes, Disease susceptibility locus, Immunogenetics, Complex genetics

Introduction

The nonobese diabetic (NOD) mouse strain spontaneously develops autoimmunity with prominent leukocytic infiltration of various tissues including the pancreas and salivary glands (1). Due to this pathology, NOD mice have become a widely used animal model for type 1 diabetes (T1D) and Sjögren’s syndrome (SjS). In the case of T1D, infiltration of the pancreatic islets (insulitis) can be first detected in NOD mice by 4–5 weeks of age, typically leading to a chronic level of β cell destruction resulting in hypoinsulinemia and hyperglycemia (reviewed in (2)). In contrast, infiltration of the salivary glands (sialadenitis) is not detectable until ≥8 weeks of age, and intrinsic abnormalities within the NOD salivary gland have been implicated in precipitating this infiltration (36). Although other mouse models exist for SjS, NOD mice appear to reflect more closely the human condition due to their age-related loss of saliva production concomitant to sialadenitis (reviewed in (7)). It has also become apparent that the similar, yet distinguishable, autoimmune pathologies for T1D and SjS are dependent on genetic factors inherited within this unique autoimmune-prone mouse strain (reviewed in (8)). One important challenge is to determine which of these factors contribute to dysregulation of the immune system and which contribute to tissue specificity of the autoimmune attack.

Linkage analyses have identified a number of loci contributing to T1D and SjS in various NOD outcross studies. Confirmation of these loci has been achieved predominantly using congenic mouse strains. To date, congenic NOD mice have confirmed T1D loci (termed Idd loci) on chromosomes (Chr) 1, 2, 3, 4, 6, 7, 11, 13, 17, and 18 (reviewed in (2, 9, 10)). Besides the MHC region on Chr17, at least five of these loci have been dissected into smaller intervals through analysis of sub-congenic NOD mice, and strong evidence has pinpointed B2m, Il2, Ctla4, Nramp1, and Trpv1 as likely genes for which NOD mice harbour T1D susceptibility alleles (1115). Preliminary evidence also suggests that Arntl2 and Stat5b are potential T1D susceptibility genes (16, 17). In contrast to T1D, fewer linkage and congenic mouse studies have been performed to identify SjS susceptibility loci. Boulard et al. notably detected linkage of sialadenitis to Chr1 and Chr3, termed Aec1 and Aec2, which overlapped two T1D susceptibility loci, termed Idd5 and Idd3 respectively (18). This genetic overlap had been identified by an earlier study in which SjS-related phenotypes were reduced in NOD mice harbouring congenic intervals for Idd5 and Idd3 (19). Conversely, placing the combined Idd5 and Idd3 NOD congenic intervals onto the C57BL/6 genetic background was sufficient to induce SjS-related phenotypes (20). A different NOD outcross study by Johansson et al. detected significant linkage to a locus on Chr4, but this locus does not appear to overlap the T1D susceptibility loci on this chromosome (18, 2123). A subsequent congenic study indicated that the NOD-derived interval for this Chr4 SjS susceptibility locus, termed Nss1, provides a relatively modest increase in sialadenitis when introduced onto the C57BL/10 background (24). As yet, the actual genes for Aec1, Aec2 and Nss1 have not been identified.

The above studies indicate that NOD alleles are required at only a few loci to initiate sialadenitis in SjS non-susceptible mouse strains, but linkage has been detected for at least one other chromosome. Boulard et al. identified linkage to Chr7, designated Ssial3, in a (NOD × NZW)F2 cross such that the NOD allele conferred susceptibility to sialadenitis (18). Interestingly, five independent genetic studies have mapped T1D susceptibility loci to either the proximal or distal ends of Chr7 (2529). The proximal locus, termed Idd7, was identified by linkage analyses of three different NOD outcrosses. Paradoxically, the non-autoimmune prone mouse strains (NON, C57BL/6, C57BL/10) were shown to contribute susceptibility alleles in the respective NOD outcrosses (2527). The distal locus was identified based on congenic mouse strains in which either C57L/J- or CBA-derived intervals conferred diabetes resistance in congenic NOD mice (28, 29). It is these distal congenic intervals that overlap Ssial3 (figure 1), suggesting that this locus may contribute to both T1D and SjS-like disease in NOD mice.

Figure 1.

Figure 1

Schematic diagram of chromosome 7 and congenic NOD mouse strains. Marker positions (Mb – left column, cM – right column) are based on NCBI Build 37 and the MGI database. The diabetes incidence and markers for the depicted congenic intervals for NOD.CBALs-Tyr+/Lt (CBA-derived Chr7 interval), NOD.Lc7 (C57L/J-derived Chr7 interval), and NOD.B6-Gpi1b/Lt (C57BL/6-derived Chr7 interval) mouse strains were previously described (28, 29). These congenic strains are depicted here for comparison purposes described in the introduction and discussion. The Idd7 and Ssial3 intervals are based upon peak linkage scores as previously described (18, 2527). The Idd? interval, which has not yet been designated an Idd number, is based upon diabetes incidence results for NOD.CBALs-Tyr+/Lt, NOD.Lc7 and NOD.B6-Gpi1b/Lt mouse strains (28, 29). Diabetes incidence and sialadenitis are described relative to NOD mice as reported here or previously (~NOD - no statistical difference between congenic and NOD mice, <NOD - congenic mice had a significant decrease for T1D incidence, nd – not determined).

It was notable that the (NOD × NZW)F2 study only detected linkage to Chr7 and Chr1 (18). In both cases, the NZW mouse strain contributed a resistant allele to F2 mice with the Chr7 allele appearing to have a greater effect in males. The limited number of detected loci within this specific NOD outcross was perhaps not surprising because NZW mice maintain a latent autoimmune predisposition (30, 31). As linkage to Chr1 had been confirmed by previous congenic mouse studies (19, 20), we generated a congenic mouse strain in which an NZW-derived Chr7 interval was placed on the NOD genetic background. We report here the characterization of this congenic NOD strain for sialadenitis, T1D incidence, ANA production and marginal-zone B-cells.

Materials and Methods

Mice

NOD/Lt (NOD) and NZW mice were bred and maintained at the Walter and Eliza Hall Institute (WEHI). NOD.NZW-Chr7D7Mit23-D7Mit370 (NOD.NZW-Chr7) congenic mice were generated by backcrossing (NOD × NZW)F1 females to NOD males. Serial backcrosses were then performed using NOD males or females and appropriate backcross progeny based on genotyping results. An NZW-derived Chr7 interval was fixed to homozygosity on the NOD background by brother-sister matings using N10 generation mice. Genotyping was performed as previously described (32). Mice were housed in a conventional animal facility for the duration of the experiments. All animal experiments described within this text were performed in Australia and comply with the current laws of Australia regarding such experiments.

Histology

Pancreata and submandibular salivary glands were harvested from euthanased mice at 150 (±10) days of age, immersed in Bouin’s fixative and embedded in paraffin. Five consecutive sections were cut from each sample ~100μm apart and ~2μm thick and stained with hematoxylin and eosin (H&E). Sialadenitis was evaluated as described by Cha et al. (20). Briefly, focus scores were calculated as the mean number of foci (aggregations of >50 mononuclear cells) per 4mm2 area of tissue after scoring whole tissue sections for total foci number. Five tissue sections per mouse were scored, compared to three tissue sections scored by Boulard et al. (18). Although we observed heterogeneity for the number of foci between tissue sections, foci having >50 mononculear cells were readily detectable. Insulitis was evaluated in pancreatic sections by scoring each individual islet as described by Charlton et al. (33).

Measurement of stimulated saliva flow rate

Mice were fasted for 6 hours with water ad libitum and injected intraperitoneally with a secretagogue comprising pilocarpine (0.005mg per 100g body weight) (Sigma) and isoproterenol (0.2mg per 100g body weight) (Sigma) dissolved in PBS. After one minute, the mouse was restrained in the hand of the operator and saliva was collected from the animal’s mouth using a micropipette for a period of 10 min. The total volume of saliva collected from each mouse was measured and normalized by weight. Samples were stored at −20°C.

Measurement of salivary protein concentration

Protein concentration in saliva samples was determined using the Bradford method as per reagent instructions (Bio-Rad, USA). Briefly, samples were diluted 1:8 in PBS and 5μl of each was added to a 96-well assay plate. BSA diluted in H2O was used as standards at concentrations of 0, 0.125, 0.25, 0.5, 0.75 and 1μg/L. 200μl of Bradford reagent (Bio-Rad, USA) was added to each standard and sample well. The plate was incubated for 15 min at room temperature. Absorbance readings were taken at 595 nm using a GENios microplate multi-detection reader (Tecan, Switzerland).

Measurement of saliva amylase activity

Saliva amylase activity was determined using the Infinity Amylase Liquid Stable Reagent (Thermo Electron Corporation, Australia) in which pNP-G7 is the substrate. Briefly, 7 μl of a 1:250 dilution of saliva was mixed with 280 μl Infinity Amylase Reagent and incubated for 60 sec at 37°C. Two absorbance readings with a 2 min interval were taken at 405 nm using a GENios microplate multidetection reader. Activity was calculated in units of activity (U) per litre according to the manufacturer’s instructions using the formula: amylase activity (U/L) = ΔAbs/min × 5140 × dilution factor.

Detection of proteolysis of Parotid Secretory Protein (PSP)

Aberrant proteolytic activity of an enzyme specific for PSP was detected using an adaptation of the method developed by Cha et al. (34). Synthetic peptide (EAVPQNLNLDVELLQQ - Mimotopes, Australia) was dissolved at 1mg/ml in 10 mM Tris-HCl pH 8.0. 8 μl of saliva sample was mixed with 42 μl of peptide and incubated at 42°C for a specified time period before addition of 50 μl of 50 mM Tris-HCl pH 8.0. All samples were filtered through a 10 kDa cut-off regenerated cellulose filter unit (Millipore, USA) at 10,000 rpm using a Heraeus Biofuge pico centrifuge (Kendro Laboratory Products, USA) for 5 min then 13,000 rpm for 15 min at room temperature. Samples were automatically loaded onto a Jupiter 300-Å 5 um C18 column (250 × 4.6 mm internal diameter - Phenomenex, USA) and chromatographed using an Agilent HP1100 system (Agilent, USA). The chromatographic conditions were: 5 min loading/washing with 100% Buffer A (0.1% trifluoracetic acid (Pierce, USA) in Milli-Q water), followed by a 40 min linear gradient from 100% Buffer A to 100% Buffer B (80% acetonitrile (Mallinckrodt, USA), 0.088% trifluoracetic acid, in Milli-Q water) at a flow rate of 1 mL/min. A final 5 min equilibration to 100% Buffer A was achieved before injection of the next sample by the auto-sampler. The signal was monitored at 214 nm. Control samples (peptide alone, buffer alone, saliva alone, filtered and unfiltered saliva and peptide) were used to identify each of the peaks in the chromatograms.

Monitoring of spontaneous diabetes

Cohorts of female mice were maintained in a conventional animal facility and tested weekly from 50 days of age for elevated urinary glucose (>110 mmol/L) using Diastix reagent strips (Bayer, Australia) over a 300-day time course. Following three consecutive elevated urinary glucose readings, diabetes onset was confirmed from a tail-bleed using an Accu-Check Advantage blood glucose meter (Roche, Switzerland). Mice that did not become diabetic were euthanased at 300 days. Pancreata and SMG were harvested from each mouse and assessed for lymphocytic infiltration as detailed above.

Anti-Nuclear Antibody (ANA) detection

ANAs were detected by indirect immunofluorescence. Serum samples were diluted 1:100 in PBS. 20μl of diluted sample was placed onto each well of a HEp-2 coated slide (Immuno Concepts, USA) and incubated for 30 min in a humidified container. Each well was washed with PBS before addition of sheep anti-mouse IgG-FITC antibody (Silenus, Australia) and humid incubation for a further 30 mins. Slides were washed and cover slips mounted using Fluorescent Mounting Medium (Dako, Denmark). Slides were viewed by fluorescent microscopy and scored as described by Hesselstrand et al. (35). Each sample was assigned a score of 0, 1, 2 or 3, with 0 being no nuclear fluorescence, and 3 being high intensity staining. Double blind scoring was performed for all samples.

Flow Cytometric Analysis

Spleens were harvested from non-diabetic mice at ~70 (±5) or 150 (±10) days of age. Cell suspensions were made by gently grinding each organ between the frosted ends of glass microscope slides (Menzel Glaser, Germany) into PBA buffer (0.1% BSA, 0.1% sodium azide in MT-PBS). Red blood cells were depleted using red cell lysis buffer (10 mM potassium bicarbonate, 150 mM ammonium chloride, 0.1 mM EDTA, 5% heat inactivated FCS, in water). Cells were washed with PBA before labelling for flow cytometry analysis. Cell suspensions were labelled with the following fluorochrome-conjugated antibodies: anti-B220 (RA3-6B2), anti-CD21, anti-CD1d, and anti-CD23 (B3B4) (Becton Dickinson (BD)). Secondary antibodies were used as required. Calibration beads (BD) were added to each sample prior to analysis for estimation of cell counts. All samples were run on a FACSCalibur (BD) flow cytometer and analysed using FlowJo software (Tree Star).

Statistical Analysis

Pair-wise comparison of diabetes incidence curves was performed using a log-rank test. Comparison of ANA scores from different groups was performed using a Mann-Whitney test. All other results were evaluated using unpaired Student’s t-tests.

Results

The region containing Ssial3 is located on mouse Chr7 between D7Mit213 and D7Mit242 with the peak linkage occurring at D7Mit53 (Fig. 1, (18)). To begin defining this locus, we generated a congenic NOD mouse strain that contained an NZW-derived interval for Chr7 on the NOD genetic background. Although the distal portion of the NZW interval was irrevocably lost during the generation of the NOD.NZW-Chr7 mouse strain, the NZW-derived interval still encompassed D7Mit53 (Fig. 1) and these congenic mice were characterized for SjS- and T1D-related phenotypes.

Severity of sialadenitis, but not insulitis, is reduced in NOD.NZW-Chr7 mice

Sialadenitis appears as periductal lymphocytic foci within the glandular architecture of the NOD submandibular salivary gland. It has been previously noted that NOD females exhibit a higher sialadenitis incidence than NOD males with detection of Chr7 linkage most evident in (NOD × NZW)F2 males (36, 37). To assess this sex bias, female and male non-diabetic cohorts of NOD and NOD.NZW-Chr7 mice were examined for sialadenitis at 150 (±10) days of age, the time point for which linkage was initially detected (18). As expected, NOD females demonstrated a significantly higher inflammatory focus score than NOD males (P<0.001, Fig. 2a). A similar trend was observed between congenic females and males, but congenic mice of both sexes demonstrated a significant reduction in lymphocytic infiltration of the salivary gland compared to NOD mice, but not as low as observed in NZW mice (Fig. 2A). This result provided confirmation and localization of the previous linkage to Chr7 (18), but suggests one or more of the other Ssial loci contributes to sialadenitis in the NOD.NZW-Chr7 congenic mouse. The reduction in lymphocytic infiltration was tissue-specific because the NZW-derived interval did not result in a significant reduction in insulitis between these same NOD and congenic mouse cohorts (Fig. 2B).

Figure 2.

Figure 2

Histological analysis of submandibular glands and pancreata for female and male cohorts of NOD, NOD.NZW-Chr7 and NZW mice. Tissues were removed from non-diabetic mice at 150 (±10) days of age and stained with H&E. A, Sialadenitis was determined by scoring the number of lymphocytic foci for which a single focus was defined as >50 mononuclear cells per 4 mm2 section (bars indicate mean ± standard error, statistical differences noted by P values). Sex matched NOD, congenic and NZW mice displayed significantly different mean focus scores with congenic mice exhibiting less infiltration than NOD mice, but greater than NZW mice. B, Insulitis was scored as follows: 0 = no infiltration, 1 = peri-insulitis, 2 = <25% of the islet infiltrated, 3 = >25% of the islet infiltrated, 4 = islet completely infiltrated. Five pancreatic sections were scored per mouse (n=10 for each group). No difference was observed between NOD and congenic mouse cohorts for insulitis.

Saliva flow rate and composition are unaltered in NOD.NZW-Chr7 mice

The complications associated with SjS, such as dental caries and increased oral bacterial infections, are attributed in part to secretory hypofunction (38). Previous studies have shown that NOD mice older than 140 days of age, subsequent to sialadenitis, have a significant reduction in their capacity to produce saliva upon stimulation (3941). To determine if the reduction of sialadenitis can ameliorate salivary gland dysfunction observed in NOD mice, we compared saliva flow rate between NOD, NOD.NZW-Chr7 and NZW mice. Stimulated saliva flow rate was measured in female and male cohorts (NOD and congenic mice were non-diabetic) after administration of a secretagogue at 150 (±10) days of age. NOD and congenic mice exhibited similar mean normalized flow rates, which were within the range of normalized rates observed for similarly aged NOD mice in other studies (Fig. 3, (42, 43)). NZW mice exhibited higher mean saliva flow rates than NOD and congenic mice, but due to large variation in male mice only the female difference was statistically significant (Fig. 3). In either case, reduced sialadenitis did not result in improved saliva production in NOD.NZW-Chr7 mice compared to NOD mice.

Figure 3.

Figure 3

Saliva flow rates for female and male cohorts of NOD, NOD.NZW-Chr7 and NZW mice. Saliva was collected for ten minutes following administration of a secretagogue to non-diabetic mice at 150 (±10) days of age. Saliva flow rate, as adjusted for body weight, was not statistically different between NOD and congenic mouse cohorts (bars indicate mean ± standard error).

In addition to sialadenitis and reduced saliva flow rate, the biochemical properties of saliva are also known to alter as NOD mice age and develop SjS-like disease. Elevated protein concentration and decreased amylase activity are often used as SjS markers in NOD mice (3, 39, 44). Saliva samples were further assessed for these other SjS-related phenotypes. As observed for saliva flow rate, the levels of saliva protein concentration and amylase activity were not significantly different (P<0.05) between NOD and congenic mice, except for a relatively small difference (P=0.04) between NOD and congenic females (Table 1). Curiously, NZW mice exhibited the highest saliva protein concentration of the three strains tested despite the relative absence of sialadenitis (Table 1).

Table 1.

Saliva protein concentration and amylase activity

Genotype Mean Protein Concentration ± SEM (μg/μl) Mean Amylase Activity ± SEM (U/L × 105)
NOD Female (n=14) 6.50 ± 0.87 1.86 ± 0.32
NOD.NZW-Chr7 Female (n=14) 4.27 ± 0.53 b 2.55 ± 0.45
NZW Female (n=20) 9.26 ± 0.95 a 3.36 ± 0.42 b
NOD Male (n=14) 6.31 ± 0.98 2.44 ± 0.34
NOD.NZW-Chr7 Male (n=17) 8.57 ± 0.88 2.50 ± 0.29
NZW Male (n=19) 9.81 ± 1.61 2.98 ± 0.33

SEM – standard error of the mean

a

P value <0.05 with respect to NOD.NZW-Chr7 mice for given sex

b

P value <0.05 with respect to NOD mice for given sex

Another biochemical marker of aberrant saliva in aged NOD mice is the increased presence of a serine protease that is capable of cleaving PSP (34). This proteolytic enzyme is yet to be identified, but its activity in saliva can be detected by quantifying cleaved PSP products using reverse-phase high performance liquid chromatography (RP-HPLC). Synthetic peptide containing the NLNL cleavage sequence from PSP was incubated with saliva samples obtained from the flow rate experiment. A preliminary experiment was performed using samples from two NOD males and two NOD females to quantify peptide cleavage at various incubation time points (0 min, 5 min, 30 min, 2 hrs, 6 hrs, 16 hrs; data not shown). Although not reported in previous studies (34, 45, 46), we observed a sex bias for peptide cleavage such that male saliva cleaved peptide more quickly than female saliva, presumably due to male saliva containing a higher concentration of PSP protease (Fig. 4B & 4C). After a 16-hr incubation, however, both sexes of NOD, NOD.NZW-Chr7 and NZW mice demonstrated pronounced serine protease activity (mean peptide cleavage >30%) based on PSP peptide cleavage (Fig. 4C), suggesting that the NZW-derived interval for Chr7 does not significantly affect this SjS-associated phenotype in congenic NOD mice. The combined saliva composition data also suggests that NZW mice, for which these traits have not been previously reported, may develop certain saliva abnormalities (PSP proteolytic cleavage, protein concentration), but they are not correlated with sialadenitis or saliva flow rate as observed in NOD mice.

Figure 4.

Figure 4

Detection of PSP proteolytic activity in saliva of female and male cohorts of NOD, NOD.NZW-Chr7 and NZW mice. Saliva was collected from individual mice at 150 (±10) days of age and incubated with a synthetic peptide containing the PSP NLNL cleavage site for activated proteases. Saliva and peptide were incubated for 5 min and 16 hrs. A, representative profiles of elution fractions from RP-HPLC analysis. Chromatographic conditions are described in Material and Methods. The intact synthetic peptide elutes at ~22.9 min (A arrow) and the two cleavage products elute at ~17.5 min and ~21.8 min (B arrows). B, proteolytic activity was measured as the percentage of the intact peptide peak area remaining after incubation. After a 5 min incubation, saliva from male mice exhibited greater PSP proteolytic activity compared to saliva from female mice. No difference was observed between female NOD and female congenic mice, but NOD males exhibited greater proteolytic activity than congenic males. C, after 16 hrs incubation, saliva from all mice exhibited peptide cleavage. Unlike NOD and congenic females, all NOD and congenic males exhibited essentially complete digestion as little to no intact peptide was detected after incubation (for B & C, bars indicate mean ± standard error).

NOD.NZW-Chr7 mice develop T1D and have an increase in ANA production

Although no difference for insulitis was observed between NOD and NOD.NZW-Chr7 mice, diabetes onset was also assessed because previous congenic studies indicated that T1D could be delayed or prevented despite the presence of insulitis (22, 23, 28, 29). Female and male cohorts of NOD and NOD.NZW-Chr7 mice were monitored for diabetes onset for 300 days (Fig. 5). Similar to sialadenitis, females demonstrated a higher diabetes incidence, and these results reflect the values typically observed in the WEHI conventional animal facility for female and male mice (47). While there was a noticeable difference between the diabetes incidence curves between NOD and congenic mice, the observed decrease was not statistically significant in either female or male comparisons between NOD and congenic mice (P>0.10), as ascertained by a log-rank test. If there is a T1D susceptibility locus within this congenic interval, then NZW mice harbour an allele that has a relatively small effect on T1D pathogenesis when placed on the NOD genetic background.

Figure 5.

Figure 5

Cumulative diabetes incidence curves for NOD and NOD.NZW-Chr7 mice. Cohorts of female (A) and male (B) mice were monitored weekly for increased urinary glucose. Congenic mice were homozygous for the NZW-derived Chr7 interval (Fig. 1). Mice with three consecutive readings >110 mmol/L were diagnosed as diabetic. Congenic mice of both sexes exhibited a small decrease in diabetes incidence compared to NOD control mice, but this difference was not statistically significant.

The presence of serum ANAs is a diagnostic criterion in human SjS (38, 48), and also a systemic autoimmune phenotype in the NOD mouse strain, although the level of ANA production appears to vary between NOD mouse colonies (38, 43, 44, 48, 49). Serum was obtained from female and male cohorts of non-diabetic NOD, NZW and NOD.NZW-Chr7 mice at 150 (±10) days of age and assessed for the presence of ANAs. Different levels of ANAs were observed based on the presence of antibody to nuclear components of HEp-2 cells, with NZW mice having the lowest median score for the three mouse strains (Fig. 6). This low score for NZW mice was similar to previous reports (30, 31, 50, 51), and suggested that there is little to no ANA production in this mouse strain. Congenic females, on the other hand, had the highest median ANA score, which was significantly higher than that of NOD females, a difference not observed between congenic and NOD males (Fig. 6). This result indicates that the NZW-derived interval is able to exacerbate this autoimmune phenotype in a sex-specific fashion when placed on the NOD genetic background, and suggests an interaction between gene(s) in this interval and the NOD background such that the congenic ANA production exceeds either of the parental strains.

Figure 6.

Figure 6

Detection of ANAs in female and male cohorts of NOD, NZW and NOD.NZW-Chr7 mice. Serum samples were obtained from mice at 150 (±10) days of age and incubated with HEp-2 coated slides. Fluorescent secondary antibody staining was detected by fluorescence microscopy and scored 0, 1, 2, or 3 with 0 having no nuclear fluorescence and 3 having high intensity staining (statistical differences noted by P values). Serum from female congenic mice typically had higher levels of ANAs than serum from NOD females, whereas no difference was observed between male NOD and congenic mice. NZW mice had significantly lower ANA levels than NOD and congenic mice.

NOD.NZW-Chr7 mice exhibit an increase in the frequency of splenic marginal-zone B-cells

Recent studies have highlighted the role of B cells in the development of SjS-like disease in mice (reviewed in (52)). In particular, an increase in marginal-zone B-cells (MZBs) have been correlated with SjS-like disease in C57BL/6 congenic mice, harbouring NOD-derived intervals for Idd3 and Idd5, and in C57BL/6 BAFF transgenic mice (46, 53). Although sialadenitis was reduced, we hypothesized that an increased level of MZBs may be correlated with saliva abnormalities (eg flow rate, PSP proteolytic activity) observed in congenic mice. Splenic lymphocytes isolated from female and male cohorts of non-diabetic NOD, NZW and NOD.NZW-Chr7 mice were assessed at ~70 and ~150 days of age by flow cytometry to determine if there is a difference for the MZB population at a time point when sialadenitis is present in NOD mice. There was a detectable increase in MZB cell frequency from 70 to 150 days of age for all mouse strains, but congenic female mice exhibited the highest number and frequency of MZB cells at 150 days of age (Figure 7). Congenic male mice also demonstrated an increased frequency in MZB cells compared to NOD and NZW males at 150 days of age, but no difference was observed for total number (Fig. 7E & F). The reason for the difference in total number of MZBs between congenic female and male mice is not clear, but congenic females did exhibit an increased number of total splenic lymphocytes compared to all congenic males, as well as NOD and NZW mice of both sexes at 150 days of age (Fig. 7G). These differences also reflect the sex bias observed for sialadenitis (Fig. 2A) and ANA production (Fig. 6), specifically that females have more severe sialadenitis and higher ANA production compared to males.

Figure 7.

Figure 7

Flow cytometric analysis of splenic MZB in NOD and NOD.NZW-Chr7 mice. Single cell suspensions of splenocytes were prepared from mice at ~70 (B, C, D) or ~150 (E, F, G) days of age. Splenic lymphocytes were stained for B220, CD23, CD21 and CD1d. A, Representative FACS profiles of CD21 and CD1d antibody staining on B220+CD23lo gated splenocytes. B, C, and D, proportion and number of splenic MZB cells and total splenic lymphocytes at 70 days of age. Congenic mice exhibited relatively higher levels of MZB cells compared to NOD and NZW mice at this time point. E, F, and G, proportion and number of splenic MZB cells and total splenic lymphocytes at 150 days of age. All strains exhibited an increase in MZB cell frequency at 150 days of age, but congenic mice, in particular females, exhibited the largest increase from 70 days of age and had the highest frequency and number of MZB cells compared to NOD and NZW mice at 150 days of age. Bars indicate mean ± standard error.

Discussion

The initial step in testing the role of Ssial3 in SjS and T1D was to generate a congenic mouse strain for the previously linked region on Chr7 (18). In this study, we replaced the NOD Ssial3 Chr7 interval with the NZW-derived interval, which was predicted to be protective. The resulting congenic mouse strain, NOD.NZW-Chr7, demonstrated a significant reduction for sialadenitis compared to NOD mice. This result provided confirmation of the previous linkage of sialadenitis to Chr7. However, NZW homozygosity for the Ssial3 locus does not entirely eliminate salivary gland infiltration because no female and very few male NOD.NZW-Chr7 mice were completely free from sialadenitis as defined by the presence of lymphocytic foci. Boulard et al. observed that NZW mice exhibit minor infiltration of the salivary glands by 300 days of age despite having a protective allele for this locus (18). Thus, it is not unexpected that the NZW-derived Chr7 interval did not completely eliminate sialadenitis in congenic NOD mice. Other loci on Chr1 (Ssial1/Aec2), Chr3 (Ssial2/Aec1), and Chr4 (Nss1) have been shown to contribute to sialadenitis susceptibility, and protective alleles at these combined loci may be necessary to provide complete protection against SjS-like disease in NOD mice (19, 21). It was also noted that linkage to the distal end of Chr7 was strongest in males (18). Nevertheless, our results indicate that the NZW allele for this locus reduces sialadenitis in male and female congenic mice.

Despite significant reduction of sialadenitis in NOD.NZW-Chr7 mice, the NZW-derived interval did not ameliorate saliva abnormalities associated with SjS-like disease in NOD mice. Congenic mice exhibited similar saliva flow rates and little to no difference for saliva biochemical properties (eg amylase activity, protein concentration and PSP protease activity) compared to NOD mice. A predominant model suggests that genetically influenced morphological disruption of the salivary glands occurs via delayed organogenesis and anomalous acinar apoptosis. This morphological disruption precipitates inflammation with subsequent lymphocytic foci initially consisting of T cells, followed by B-cell recruitment. The onset of disease, defined principally by hyposalivation, is then mediated by the combination of acinar destruction, autoantibodies and pro-inflammatory cytokines, likely produced by invading lymphocytes (3, 6, 34, 41, 43). Conversely, it has been proposed that reduced salivary secretion occurs independently of sialadenitis, but inflammation, once established, exacerbates salivary gland dysfunction (42). The reduced sialadenitis observed in NOD.NZWChr7 mice, without the concomitant changes in saliva flow rate and composition, would seem to support this second model. However, NOD.scid mice lack development of sialadenitis and do not exhibit a loss of saliva gland secretory function (3). It is therefore likely that some level of lymphocytic infiltration and destructive activity is required for overt SjS-like disease to develop in NOD mice. The relatively low level of sialadenitis in NOD.NZW-Chr7 mice is apparently enough to alter saliva flow rate and composition.

In contrast to reduced sialadenitis, female NOD.NZW-Chr7 mice exhibited an increase in ANA production and both sexes exhibited increased splenic MZB frequency at 150 days of age. These phenotypes were unexpected because NZW mice demonstrated little to no ANA production and had a lower MZB frequency than congenic mice. The combination of the NZW-derived Chr7 interval on the NOD background appears to allow an epistatic interaction leading to greater phenotypic expression not observed in either of the parental NOD or NZW mice. A similar increase in ANA production was observed in another congenic NOD strain, which harboured a C57BL/10 interval for Idd9.3 on Chr4; whereas C57BL/10 mice do not exhibit ANA production (54). Interestingly, the NZW-derived interval in the NOD.NZW-Chr7 strain overlaps the defined Sle3 locus, which is linked to ANA development in the NZW/B model of systemic lupus erythematosus (55). Subsequent congenic analyses dissected the Sle3 locus and demonstrated that an NZW-derived allele could increase ANA production when placed on the C57BL/6 background (56). Notably, increased ANA production in these three congenic mouse examples is the result of epistatic interactions. This might be expected as severe disease, including nephritis and high levels of ANA production, is not apparent in NZW or NZB, but develops in their F1 hybrid (57). Further studies of NOD.NZW-Chr7 mice are required to determine if they develop other lupus-related phenotypes.

The role of B cells is critical for the development of overt SjS in NOD mice because NOD.Igμnull mice maintain normal saliva secretion despite extensive leukocytic infiltration of the salivary gland (58). ANAs, on the other hand, do not appear to have a direct role in SjS-like disease in NOD mice (43); but our observed increase in ANA production suggests that the B cell compartment of NOD.NZW-Chr7 female mice may be adversely affected by the congenic interval. A potential reservoir of autoreactive B cells is the MZB population (reviewed in (59)), which has been implicated in mouse models of SjS-like disease (46, 53). MZBs are also increased in NOD mice compared to non-autoimmune-prone mouse strains (60, 61). The larger increase in splenic MZB frequency for NOD.NZW-Chr7 mice as they age may contribute to a more pathogenic infiltrate despite a decrease in the number of lymphocytic foci within the salivary glands of these mice. It will, therefore, be of interest to determine if subsequent subcongenic mouse strains, which dissect the Chr7 interval, segregate these various phenotypes that differ between NOD and NOD.NZW-Chr7 mice.

Genetic studies indicate that there are overlapping and distinct loci that contribute to SjS and T1D in the NOD mouse. Chr1 and Chr3, in particular, have been shown to harbour overlapping loci (Idd5/Aec1 and Idd3/Aec2) that can affect pathogenesis for both diseases (19, 20, 45). Sialadenitis, however, is not a direct result of diabetes onset because NOD mice that are congenic for a different MHC locus are protected from diabetes, but still develop sialadenitis and salivary gland dysfunction (44). Furthermore, congenic mouse strains for a number of non-MHC Idd loci were also not protected from SjS-like disease (19). With this in mind, we monitored NOD.NZW-Chr7 mice for insulitis and T1D onset because these mice harboured a congenic interval that overlapped two different regions on Chr7 implicated in T1D pathogenesis (Fig. 1). Despite conferring reduced sialadenitis, this NZW-derived congenic interval did not have a significant effect upon insulitis when placed onto the NOD genetic background. This result suggests that the NZW allele for Ssial3 has a more pronounced effect upon sialadenitis compared to insulitis. At best, this congenic interval resulted in a small decrease in T1D incidence for which the size of our mouse cohorts was statistically underpowered to detect. Whereas, the increased frequency of splenic MZB, which have been implicated in T1D pathogenesis (61), was not associated with exacerbation of T1D onset in NOD.NZW-Chr7 mice.

The contribution of Chr7 to autoimmunity in NOD mice is complex. At least two loci on this chromosome are implicated in T1D pathogenesis (18, 2529). The congenic interval in NOD.NZW-Chr7 mice is relatively large (~97Mb) and partially overlaps both T1D loci (Fig. 1). Previous linkage studies indicate that non-autoimmune prone mouse strains (NON, C57BL/6, C57BL/10) harbour a susceptibility allele for a proximal T1D locus, termed Idd7 (2527). The NZW-derived interval, however, did not exacerbate T1D in NOD.NZW-Chr7 mice, suggesting that the Idd7 locus is either proximal to the congenic interval or the NZW allele is different from that harboured by NON, C57BL/6 and C57BL/10 mice. Interestingly, a C57BL/6-derived interval, which is encompassed by our NZW-derived interval (Fig. 1), was also unable to exacerbate T1D in congenic NOD mice (29). This result indicated that Idd7 mapped proximal to this C57BL/6-derived interval, but a subsequent study demonstrated that this interval could affect TCR expression levels and thymic deletion of diabetogenic T cells (62). It may be that there are actually two T1D loci on the proximal end of Chr7 as proposed by Gonzalez et al. in their linkage study, in which case C57BL/6 alleles may be required at both of these loci on the NOD genetic background to exacerbate T1D (27). The distal end of Chr7 was also confirmed to harbour a T1D locus by two independent congenic mouse strains (28, 29). These congenic strains harbour different, but overlapping, intervals derived from CBA/LsLt and C57L/J mice (Fig. 1). And while they may represent different loci, both strains demonstrated significant decreases in T1D incidence (28, 29). NOD.NZW-Chr7 mice, on the other hand, were not significantly protected, suggesting that a T1D locus maps distal to the NZW-derived interval or that the NZW allele is different to that harboured by CBA/LsLt and C57L/J mice.

SjS and T1D represent polygenic autoimmune diseases with complex aetiologies. The congenic study presented here has confirmed Ssial3 on Chr7 as the fourth locus related to SjS-like disease in NOD mice. While the NZW-derived allele can moderate sialadenitis, it did not prevent the diagnostic symptoms of SjS. Ssial3 also appears to be a distinct locus for sialadenitis because insulitis and T1D incidence were not significantly altered in congenic mice. The anomalous increase in ANA production and MZB frequency indicates that the NZW-derived interval has a complex effect on the NOD immune system due to epistatic interactions between the unique combination of NZW and NOD alleles present in NOD.NZW-Chr7 mice. Comparison of various congenic NOD mouse strains also points to more than one autoimmunity locus on Chr7 and further investigation using different strain-derived intervals, which dissect this chromosome, will most likely be required to precisely map and identify the contribution of allelic variation for the underlying genes.

Acknowledgments

The authors thank Melissa Smith, Gabriela Panoschi, Keti Stoev, Andrea Morcom, Sarah Jones, and Alex Delbridge for technical assistance, and Dr David M. Tarlinton for providing antibodies and technical advice, and Dr Pablo Silveira and Dr Colleen Elso for helpful discussions.

Abbreviations used in this paper

SjS

Sjögren’s syndrome

T1D

type 1 diabetes

NOD

nonobese diabetic

Chr

chromosome

H&E

hematoxylin and eosin

PSP

parotid secretory protein

ANA

anti-nuclear antibody

MZB

marginal-zone B-cell

Footnotes

1

This work was supported in part by Award Number R01DK062882 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Award Number 1-2005-925 from the Juvenile Diabetes Research Foundation (JDRF). R.A.B. was supported by a grant in aid from Multiple Sclerosis Research Australia. L.W. was supported by an Alan W. Harris Scholarship. I.T.K.L. was supported by a Melbourne International Research Scholarship. N.W. was supported by an Australian Postgraduate Award. T.C.B. was supported by the Syme Fellowship.

References

  • 1.Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980;29:1–13. doi: 10.1538/expanim1978.29.1_1. [DOI] [PubMed] [Google Scholar]
  • 2.Serreze DV, Leiter EH. Genes and cellular requirements for autoimmune diabetes susceptibility in nonobese diabetic mice. Curr Dir Autoimmun. 2001;4:31–67. doi: 10.1159/000060527. [DOI] [PubMed] [Google Scholar]
  • 3.Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin immunol Immunopathol. 1996;79:50–59. doi: 10.1006/clin.1996.0050. [DOI] [PubMed] [Google Scholar]
  • 4.Robinson CP, Yamachika S, Alford CE, Cooper C, Pichardo EL, Shah N, Peck AB, Humphreys-Beher MG. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjogren syndrome. Proc Natl Acad Sci U S A. 1997;94:5767–5771. doi: 10.1073/pnas.94.11.5767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kong L, Robinson CP, Peck AB, Vela-Roch N, Sakata KM, Dang H, Talal N, Humphreys-Beher MG. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol. 1998;16:675–681. [PubMed] [Google Scholar]
  • 6.Cha S, van Blockland SC, Versnel MA, Homo-Delarche F, Nagashima H, Brayer J, Peck AB, Humphreys-Beher MG. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet. 2001;18:143–160. doi: 10.1159/000049194. [DOI] [PubMed] [Google Scholar]
  • 7.Jonsson MV, Delaleu N, Jonsson R. Animal models of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2007;32:215–224. doi: 10.1007/s12016-007-8012-7. [DOI] [PubMed] [Google Scholar]
  • 8.Johansson AC, Lindqvist AK, Johannesson M, Holmdahl R. Genetic heterogeneity of autoimmune disorders in the nonobese diabetic mouse. Scand J Immunol. 2003;57:203–213. doi: 10.1046/j.1365-3083.2003.01235.x. [DOI] [PubMed] [Google Scholar]
  • 9.Lang J, Bellgrau D. Animal models of type 1 diabetes: genetics and immunological function. Adv Exp Med Biol. 2004;552:91–116. [PubMed] [Google Scholar]
  • 10.Leiter EH. Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep. 2005;5:141–148. doi: 10.1007/s11892-005-0042-z. [DOI] [PubMed] [Google Scholar]
  • 11.Hamilton-Williams EE, Serreze DV, Charlton B, Johnson EA, Marron MP, Mullbacher A, Slattery RM. Transgenic rescue implicates β2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc Natl Acad Sci U S A. 2001;98:11533–11538. doi: 10.1073/pnas.191383798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–511. doi: 10.1038/nature01621. [DOI] [PubMed] [Google Scholar]
  • 13.Kissler S, Stern P, Takahashi K, Hunter K, Peterson LB, Wicker L. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat Genet. 2006;38:479–483. doi: 10.1038/ng1766. [DOI] [PubMed] [Google Scholar]
  • 14.Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, Chen SL, Rosa R, Cumiskey AM, Serreze DV, Gregory S, Rogers J, Lyons PA, Healy B, Smink LJ, Todd JA, Peterson LB, Wicker LS, Santamaria P. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet. 2007;39:329–337. doi: 10.1038/ng1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Razavi R, Chan Y, Afifiyan FN, Liu XJ, Wan X, Yantha J, Tsui H, Tang L, Tsai S, Santamaria P, Driver JP, Serreze D, Salter MW, Dosch MH. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune disease. Cell. 2006;127:1123–1135. doi: 10.1016/j.cell.2006.10.038. [DOI] [PubMed] [Google Scholar]
  • 16.Hung MS, Avner P, Rogner UC. Identification of the transcription factor Arntl2 as a candidate gene for the type 1 diabetes locus Idd6. Hum Mol Genet. 2006 doi: 10.1093/hmg/ddl209. [DOI] [PubMed] [Google Scholar]
  • 17.Laloraya M, Davoodi-Semiromi A, Kumar GP, McDuffie M, She JX. Impaired Crkl expression contributes to the defective DNA binding of Stat5b in nonobese diabetic mice. Diabetes. 2006;55:734–741. doi: 10.2337/diabetes.55.03.06.db05-1059. [DOI] [PubMed] [Google Scholar]
  • 18.Boulard O, Fluteau G, Eloy L, Damotte D, Bedossa P, Garchon HJ. Genetic analysis of autoimmune sialadenitis in nonobese diabetic mice: a major susceptibility region on chromosome 1. J Immunol. 2002;168:4192–4201. doi: 10.4049/jimmunol.168.8.4192. [DOI] [PubMed] [Google Scholar]
  • 19.Brayer J, Lowry J, Cha S, Robinson CP, Yamachika S, Peck AB, Humphreys-Beher MG. Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjogren’s syndrome-like autoimmune exocrinopathy. J Rheumatol. 2000;27:1896–1904. [PubMed] [Google Scholar]
  • 20.Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren’s syndrome) on a healthy murine background. Arthritis Rheum. 2002;46:1390–1398. doi: 10.1002/art.10258. [DOI] [PubMed] [Google Scholar]
  • 21.Johansson AC, Nakken B, Sundler M, Lindqvist AK, Johannesson M, Alarcon-Riquelme M, Bolstad AI, Humphreys-Beher MG, Jonsson R, Skarstein K, Holmdahl R. The genetic control of sialadenitis versus arthritis in a NOD.QxB10.Q F2 cross. Eur J Immunol. 2002;32:243–250. doi: 10.1002/1521-4141(200201)32:1<243::AID-IMMU243>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 22.Brodnicki TC, Fletcher AL, Pellicci DG, Berzins SP, McClive P, Quirk F, Webster KE, Scott HS, Boyd RL, Godfrey DI, Morahan G. Localization of Idd11 Is Not Associated With Thymus and NKT Cell Abnormalities in NOD Mice. Diabetes. 2005;54:3453–3457. doi: 10.2337/diabetes.54.12.3453. [DOI] [PubMed] [Google Scholar]
  • 23.Lyons PA, Hancock WW, Denny P, Lord CJ, Hill NJ, Armitage N, Siegmund T, Todd JA, Phillips MS, Hess JF, Chen SL, Fischer PA, Peterson LB, Wicker LS. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity. 2000;13:107–115. doi: 10.1016/s1074-7613(00)00012-1. [DOI] [PubMed] [Google Scholar]
  • 24.Hjelmervik TO, Lindqvist AK, Petersen K, Johannesson M, Stavrum AK, Johansson A, Jonsson R, Holmdahl R, Bolstad AI. The influence of the NOD Nss1/Idd5 loci on sialadenitis and gene expression in salivary glands of congenic mice. Arthritis Res Ther. 2007;9:R99. doi: 10.1186/ar2300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ghosh S, Palmer SM, Rodrigues NR, Cordell HJ, Hearne CM, Cornall RJ, Prins JB, McShane P, Lathrop GM, Peterson LB, et al. Polygenic control of autoimmune diabetes in nonobese diabetic mice. Nat Genet. 1993;4:404–409. doi: 10.1038/ng0893-404. [DOI] [PubMed] [Google Scholar]
  • 26.McAleer MA, Reifsnyder P, Palmer SM, Prochazka M, Love JM, Copeman JB, Powell EE, Rodrigues NR, Prins JB, Serreze DV, et al. Crosses of NOD mice with the related NON strain. A polygenic model for IDDM. Diabetes. 1995;44:1186–1195. doi: 10.2337/diab.44.10.1186. [DOI] [PubMed] [Google Scholar]
  • 27.Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity. 1997;7:873–883. doi: 10.1016/s1074-7613(00)80405-7. [DOI] [PubMed] [Google Scholar]
  • 28.McDuffie M. Derivation of diabetes-resistant congenic lines from the nonobese diabetic mouse. Clin Immunol. 2000;96:119–130. doi: 10.1006/clim.2000.4893. [DOI] [PubMed] [Google Scholar]
  • 29.Chen J, Reifsnyder PC, Scheuplein F, Schott WH, Mileikovsky M, Soodeen-Karamath S, Nagy A, Dosch MH, Ellis J, Koch-Nolte F, Leiter EH. “Agouti NOD”: identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells. Mamm Genome. 2005;16:775–783. doi: 10.1007/s00335-005-0007-1. [DOI] [PubMed] [Google Scholar]
  • 30.Kelley VE, Winkelstein A. Age- and sex-related glomerulonephritis in New Zealand white mice. Clin Immunol Immunopathol. 1980;16:142–150. doi: 10.1016/0090-1229(80)90198-1. [DOI] [PubMed] [Google Scholar]
  • 31.Kotzin BL, Palmer E. The contribution of NZW genes to lupus-like disease in (NZB × NZW)F1 mice. J Exp Med. 1987;165:1237–1251. doi: 10.1084/jem.165.5.1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Dietrich W, Katz H, Lincoln SE, Shin HS, Friedman J, Dracopoli NC, Lander ES. A genetic map of the mouse suitable for typing intraspecific crosses. Genetics. 1992;131:423–447. doi: 10.1093/genetics/131.2.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Charlton B, Mandel TE. Progression from insulitis to beta-cell destruction in NOD mouse requires L3T4+ T-lymphocytes. Diabetes. 1988;37:1108–1112. doi: 10.2337/diab.37.8.1108. [DOI] [PubMed] [Google Scholar]
  • 34.Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, Peck AB. A dual role for interferon-gamma in the pathogenesis of Sjogren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol. 2004;60:552–565. doi: 10.1111/j.0300-9475.2004.01508.x. [DOI] [PubMed] [Google Scholar]
  • 35.Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. Rheumatology. Vol. 42. Oxford: 2003. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis; pp. 534–540. [DOI] [PubMed] [Google Scholar]
  • 36.Toda I, Sullivan BD, Rocha EM, Da Silveira LA, Wickham LA, Sullivan DA. Impact of gender on exocrine gland inflammation in mouse models of Sjogren’s syndrome. Exp Eye Res. 1999;69:355–366. doi: 10.1006/exer.1999.0715. [DOI] [PubMed] [Google Scholar]
  • 37.Boulard O, Damotte D, Deruytter N, Fluteau G, Carnaud C, Garchon HJ. An interval tightly linked to but distinct from the H2 complex controls both overt diabetes (Idd16) and chronic experimental autoimmune thyroiditis (Ceat1) in nonobese diabetic mice. Diabetes. 2002;51:2141–2147. doi: 10.2337/diabetes.51.7.2141. [DOI] [PubMed] [Google Scholar]
  • 38.Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321–331. doi: 10.1016/S0140-6736(05)66990-5. [DOI] [PubMed] [Google Scholar]
  • 39.Hu Y, Nakagawa Y, Purushotham KR, Humphreys-Beher MG. Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol. 1992;263:E607–614. doi: 10.1152/ajpendo.1992.263.4.E607. [DOI] [PubMed] [Google Scholar]
  • 40.Humphreys-Beher MG, Hu Y, Nakagawa Y, Wang PL, Purushotham KR. Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren’s syndrome. Adv Exp Med Biol. 1994;350:631–636. doi: 10.1007/978-1-4615-2417-5_105. [DOI] [PubMed] [Google Scholar]
  • 41.Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006;54:2300–2305. doi: 10.1002/art.21945. [DOI] [PubMed] [Google Scholar]
  • 42.Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Perez Leiros C. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol. 2005;142:411–418. doi: 10.1111/j.1365-2249.2005.02930.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB. Sjogren’s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun. 2006;26:90–103. doi: 10.1016/j.jaut.2005.11.004. [DOI] [PubMed] [Google Scholar]
  • 44.Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, Holmdahl R, Peck AB, Humphreys-Beher MG. A novel NOD-derived murine model of primary Sjogren’s syndrome. Arthritis Rheum. 1998;41:150–156. doi: 10.1002/1529-0131(199801)41:1<150::AID-ART18>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  • 45.Nguyen C, Singson E, Kim JY, Cornelius JG, Attia R, Doyle ME, Bulosan M, Cha S, Peck AB. Sjogren’s syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus. Scand J Immunol. 2006;64:295–307. doi: 10.1111/j.1365-3083.2006.01828.x. [DOI] [PubMed] [Google Scholar]
  • 46.Nguyen CQ, Kim H, Cornelius JG, Peck AB. Development of Sjogren’s syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol. 2007;179:2318–2329. doi: 10.4049/jimmunol.179.4.2318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Brodnicki TC, Quirk F, Morahan G. A susceptibility allele from a non-diabetes-prone mouse strain accelerates diabetes in NOD congenic mice. Diabetes. 2003;52:218–222. doi: 10.2337/diabetes.52.1.218. [DOI] [PubMed] [Google Scholar]
  • 48.Humphreys-Beher MG, Brinkley L, Purushotham KR, Wang PL, Nakagawa Y, Dusek D, Kerr M, Chegini N, Chan EK. Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin Immunol Immunopathol. 1993;68:350–356. doi: 10.1006/clin.1993.1137. [DOI] [PubMed] [Google Scholar]
  • 49.Baxter AG, Healey D, Cooke A. Mycobacteria precipitate autoimmune rheumatic disease in NOD mice via an adjuvant-like activity. Scand J Immunol. 1994;39:602–606. doi: 10.1111/j.1365-3083.1994.tb03419.x. [DOI] [PubMed] [Google Scholar]
  • 50.Hahn BH, Shulman LE. Autoantibodies and nephritis in the white strain (NZW) of New Zealand mice. Arthritis Rheum. 1969;12:355–364. doi: 10.1002/art.1780120403. [DOI] [PubMed] [Google Scholar]
  • 51.Lambert PH, Dixon FJ. Genesis of antinuclear antibody in NZB-W mice: role of genetic factors and of viral infections. Clin Exp Immunol. 1970;6:829–839. [PMC free article] [PubMed] [Google Scholar]
  • 52.Nguyen CQ, Cha SR, Peck AB. Sjogren’s syndrome (SjS)-like disease of mice: the importance of B lymphocytes and autoantibodies. Front Biosci. 2007;12:1767–1789. doi: 10.2741/2187. [DOI] [PubMed] [Google Scholar]
  • 53.Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109:59–68. doi: 10.1172/JCI14121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Irie J, Wu Y, Sass DA, Ridgway WM. Genetic control of anti-Sm autoantibody production in NOD congenic mice narrowed to the Idd9.3 region. Immunogenetics. 2006;58:9–14. doi: 10.1007/s00251-005-0066-1. [DOI] [PubMed] [Google Scholar]
  • 55.Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity. 1994;1:219–229. doi: 10.1016/1074-7613(94)90100-7. [DOI] [PubMed] [Google Scholar]
  • 56.Liu K, Li QZ, Yu Y, Liang C, Subramanian S, Zeng Z, Wang HW, Xie C, Zhou XJ, Mohan C, Wakeland EK. Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis. Genes Immun. 2007;8:634–645. doi: 10.1038/sj.gene.6364426. [DOI] [PubMed] [Google Scholar]
  • 57.Helyer BJ, Howie JB. Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature. 1963;197:197. doi: 10.1038/197197a0. [DOI] [PubMed] [Google Scholar]
  • 58.Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, Peen E, Jonsson R, Humphreys-Beher MG. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren’s syndrome. Proc Natl Acad Sci U S A. 1998;95:7538–7543. doi: 10.1073/pnas.95.13.7538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol. 2002;2:323–335. doi: 10.1038/nri799. [DOI] [PubMed] [Google Scholar]
  • 60.Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol. 2004;172:5086–5094. doi: 10.4049/jimmunol.172.8.5086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Marino E, Batten M, Groom J, Walters S, Liuwantara D, Mackay F, Grey ST. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes. 2008;57:395–404. doi: 10.2337/db07-0589. [DOI] [PubMed] [Google Scholar]
  • 62.Serreze DV, Choisy-Rossi CM, Grier AE, Holl TM, Chapman HD, Gahagan JR, Osborne MA, Zhang W, King BL, Brown A, Roopenian D, Marron MP. Through Regulation of TCR Expression Levels, an Idd7 Region Gene(s) Interactively Contributes to the Impaired Thymic Deletion of Autoreactive Diabetogenic CD8+ T Cells in Nonobese Diabetic Mice. J Immunol. 2008;180:3250–3259. doi: 10.4049/jimmunol.180.5.3250. [DOI] [PubMed] [Google Scholar]

RESOURCES